A multicentre pivotal clinical trial to investigate LYS-SAF302 for the treatment of Sanfilippo Type A
Phase of Trial: Phase II/III
Latest Information Update: 16 Apr 2018
At a glance
- Drugs SAF 302 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Registrational; Therapeutic Use
- Sponsors LYSOGENE
- 16 Apr 2018 According to a Lysogene media release, this trial is expected to start in the second half of 2018.
- 06 Feb 2018 According to a LYSOGENE media release, company plans submission of Marketing Authorization Application following completion of this trial.
- 06 Feb 2018 According to a Lysogene media release, Paediatric Committee (PDCO) of the European Medicines Agency (EMA) adopted a positive opinion regarding the Paediatric Investigation Plan (PIP) for LYS-SAF302 in patients with mucopolysaccharidosis type IIIA.